Previous 10 | Next 10 |
Direxion is planning to launch the Direxion mRNA ETF to offer investors exposure to messenger RNA technology, the cutting-edge research area that served as the basis for most COVID-19 vaccines. Per a prospectus filed with the U.S. Securities and Exchange Commission, the new ETF will...
First international patient enrolled in Brazil Trial approximately 75% enrolled rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients Topline trial data anticipated in the fourth quarter of 2021 WESTMINS...
The following slide deck was published by ARCA biopharma, Inc. in conjunction with this event. For further details see: ARCA biopharma (ABIO) Investor Presentation - Slideshow
WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Jeff Dekker , Chief Financial ...
ARCA biopharma Inc. (NASDAQ: ABIO) is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing rNAPc2 as a potential treatment for diseases caused by RNA viruses, initially focusing on COV...
WESTMINSTER, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that it has submitted a Patent Cooperat...
ARCA biopharma (NASDAQ:ABIO): Q2 GAAP EPS of -$0.34. Cash and cash equivalents of $63.2M Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 expanded to South America Topline data anticipated in the fourth quarter of 2021 Shares +3.06% AH. Press Release For ...
Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 expanded to South America Topline data anticipated in the fourth quarter of 2021 WESTMINSTER, Colo., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a bioph...
Analysis in full patient cohort shows Gencaro effect compared to standard of care In the GENETIC-AF entire cohort of heart failure patients treated with Gencaro, compared to patients treated with metoprolol succinate (TOPROL-XL), experienced: a 36% reduction in cumulative atrial...
Shares of ARCA biopharma Inc. (NASDAQ:ABIO) traded today at $2.75, breaking its 52-week low. So far today approximately 102,000 shares have been exchanged, as compared to an average 30-day volume of 237,000 shares. In the past 52 weeks, ARCA biopharma Inc. share prices are bracketed by a...
News, Short Squeeze, Breakout and More Instantly...
Bank of the James Financial Group Inc. (BOTJ) is expected to report for Q2 2024 Electrolux AB ADR (ELUXY) is expected to report $-0.18 for Q2 2024 Coca Cola Femsa S.A.B. de C.V. American Depositary Shares each representing 10 Units (each Unit consists of 3 Series B Shares and 5 Series L S...
NEW YORK, NY / ACCESSWIRE / May 22, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sale...